Compare MCBS & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCBS | CMPS |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 816.1M | 788.9M |
| IPO Year | 2019 | 2020 |
| Metric | MCBS | CMPS |
|---|---|---|
| Price | $27.69 | $6.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $31.00 | $27.14 |
| AVG Volume (30 Days) | 58.1K | ★ 4.4M |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 24.75 | 0.86 |
| EPS | ★ 1.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.76 | N/A |
| Revenue Next Year | $4.83 | N/A |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.24 | $2.25 |
| 52 Week High | $31.00 | $8.90 |
| Indicator | MCBS | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 47.69 |
| Support Level | $26.90 | $5.95 |
| Resistance Level | $29.08 | $7.02 |
| Average True Range (ATR) | 0.70 | 0.53 |
| MACD | -0.15 | -0.09 |
| Stochastic Oscillator | 14.10 | 15.16 |
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.